Eczema (Atopic Dermatitis) Clinical Trials in Orlando

View 32 new treatments for Eczema (Atopic Dermatitis) in Orlando, FL. Every day, Power helps hundreds of Eczema (Atopic Dermatitis) patients connect with leading medical research.

Rocatinlimab for Eczema

Amgen Clinic, DeLand + 1 more

The primary objective of the study is to evaluate the pharmacokinetics (PK) of multiple cytochrome P450 (CYP450) substrates alone and in combination with rocatinlimab in participants with moderate to severe atopic dermatitis (AD).Show More
Waitlist

No Placebo Trial

Phase < 1
Est. 4 - 6 Weeks
MD
Study Director

Rocatinlimab for Eczema

Amgen Clinic, Orlando + 1 more

This trial is testing a new medication called rocatinlimab to see if it works well and is safe when used alone. It targets patients who might benefit from a new treatment option.Show More
Recruiting
Phase 3
Est. 6 - 12 Weeks
MD
Study Director

Amlitelimab for Atopic Dermatitis (COAST 2)

Sanofi Clinic, Orlando + 1 more

This trial tests amlitelimab injections for patients aged 12 and older with moderate to severe atopic dermatitis that isn't controlled by topical treatments. The injections aim to reduce inflammation and symptoms by targeting specific immune pathways.Show More
Recruiting
Phase 3
Est. 3 - 12 Weeks
Unregistered Study Lead
Research Team

Abrocitinib for Atopic Dermatitis/Eczema

Pfizer Clinic, Orlando + 7 more

This trial is testing a pill called Abrocitinib to help people aged 12 and older with severe eczema. It aims to see if the pill can reduce inflammation and itching by blocking certain body chemicals. The study includes patients who have already participated in a related study.Show More
Waitlist
Phase 3
Est. 4 - 6 Weeks
Pfizer CT.gov Call Center
Study Director

Linerixibat for Itching in Cholangitis

GlaxoSmithKline Clinic, Orlando + 1 more

This trial is testing a medication called linerixibat to see if it can help reduce severe itching in people with a liver condition called Primary Biliary Cholangitis (PBC). The study will compare the effects of linerixibat to check its effectiveness and safety.Show More
Waitlist
Phase 3
Est. 6 - 12 Weeks
GSK Clinical Trials
Study Director

Rocatinlimab for Atopic Dermatitis

Amgen Clinic, Orange City + 3 more

This trial is testing a medication called rocatinlimab to see if it works and is safe for teenagers. The medication can be used by itself or with other treatments. It aims to help by interacting with the immune system.Show More
Waitlist
Phase 3
Est. 3 - 6 Weeks
MD
Study Director

Ruxolitinib Cream for Prurigo Nodularis

Incyte Clinic, Orlando + 2 more

This trial tests the safety and tolerability of a cream for people with Prurigo Nodularis, a condition with itchy skin nodules. The cream works by blocking enzymes that cause inflammation and itching. It has been previously tested for its effects in conditions like atopic dermatitis.Show More
Recruiting
Phase 3
Est. 3 - 12 Weeks
Unregistered Study Lead
Research Team

Rocatinlimab for Eczema

Amgen Clinic, Kissimmee + 1 more

This trial tests the safety and tolerability of rocatinlimab in adolescents with moderate-to-severe atopic dermatitis. Rocatinlimab works by reducing inflammation and calming the immune system.Show More
Waitlist

No Placebo Trial

Phase 3
Est. 5 - 8 Weeks
MD
Study Director

Amlitelimab for Atopic Dermatitis (COAST 1)

Sanofi Clinic, Orlando + 1 more

This trial tests an injectable treatment called amlitelimab for people aged 12 and older with moderate to severe eczema that doesn't respond well to creams or ointments. The treatment aims to reduce skin inflammation and itching by blocking specific proteins in the immune system. The study will evaluate how effective and safe amlitelimab is.Show More
Recruiting
Phase 3
Est. 6 - 12 Weeks
Clinical Sciences & Operations
Study Director

Dupilumab for Itching

Sanofi Clinic, Bellair + 3 more

This trial tests a medication that reduces skin inflammation and itching in adults with severe, unexplained itching. It works by blocking proteins that cause these symptoms. The medication has shown promise in treating conditions like atopic dermatitis and asthma.Show More
Recruiting
Phase 3
Est. 3 - 12 Weeks
Unregistered Study Lead
Research Team
Page 1 of 3

Frequently Asked Questions

How much do eczema clinical trials pay?

Each trial will compensate patients a different amount, but $50-100 for each visit is a fairly common range. Further, most trials will cover the costs of an Uber to-and-from the clinic. Factors that can affect compensation include the phase of the trial, the length of the trial, the frequency of visits, and the specific condition being studied.

Do I need to be insured to participate in a medical study?

Clinical trials are almost always free to participants, and so do not require insurance. The only exception here are trials focused on Cancer, because only a small part of the typical treatment plan is actually experimental. For these cancer trials, participants typically need insurance to cover all the non-experimental components.

How do eczema clinical trials work?

After a researcher reviews your profile, they may choose to invite you in to a screening appointment, where they'll determine if you meet 100% of the eligibility requirements. If you do, you'll typical be sorted into one of the treatment groups, and will receive your study drug. For some trials, there is a chance you'll receive a placebo. Across eczema trials in Orlando, 42% of clinical trials have a placebo. Typically you'll be required to check-in with the clinic every month or two. The average trial length in this city for eczema patients is 6 Months.

What does the "phase" of a clinical trial mean?

The phase of a trial reveals what stage the drug is in getting approval for a specific condition. Phase 3 trials are in the final step before approval. The drug already has data showing both safety and effectiveness. Phase 2 trials are those where the drug has some data showing safety in humans, but where effectiveness has typically only been shown in animals and non-human experiments. Phase 1 trials are the trials where we don't have safety data in humans. As a general rule, phase 3 trials are more promising than phase 2, and phase 2 trials are more promising than phase 1.